Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Pharmacogenomics
|
September 7, 2005
Sarcomas and pharmacogenetics
Paola Biason, Giuseppe Toffoli
Pharmacology & Therapeutics
|
June 15, 2010
Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents
Michele Visentin, Paola Biason, Giuseppe Toffoli
Pharmacogenomics
|
November 15, 2012
miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?
Eva Dreussi, Paola Biason, Giuseppe Toffoli, et al.
Pharmacogenomics
|
November 15, 2012
Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy
Paola Biason, Michele Visentin, Renato Talamini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan
Erika Cecchin, Federico Innocenti, Mario D'Andrea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients
Erika Cecchin, Giuseppe Corona, Sara Masier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 20, 2009
Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival
Giuseppe Toffoli, Paola Biason, Antonio Russo, et al.
Cancer Cell International
|
February 5, 2020
The heterogeneous clinical and pathological landscapes of metastatic <i>Braf</i>-mutated colorectal cancer
Giuseppe Nicolò Fanelli, Carlo Alberto Dal Pozzo, Ilaria Depetris, et al.
Oncotarget
|
August 28, 2016
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
Claudia M Hattinger, Paola Biason, Erika Iacoboni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2006
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli, Erika Cecchin, Giuseppe Corona, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Pharmacogenomics
|
September 7, 2005
Sarcomas and pharmacogenetics
Paola Biason, Giuseppe Toffoli
Pharmacology & Therapeutics
|
June 15, 2010
Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents
Michele Visentin, Paola Biason, Giuseppe Toffoli
Pharmacogenomics
|
November 15, 2012
miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?
Eva Dreussi, Paola Biason, Giuseppe Toffoli, et al.
Pharmacogenomics
|
November 15, 2012
Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy
Paola Biason, Michele Visentin, Renato Talamini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan
Erika Cecchin, Federico Innocenti, Mario D'Andrea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients
Erika Cecchin, Giuseppe Corona, Sara Masier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 20, 2009
Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival
Giuseppe Toffoli, Paola Biason, Antonio Russo, et al.
Cancer Cell International
|
February 5, 2020
The heterogeneous clinical and pathological landscapes of metastatic <i>Braf</i>-mutated colorectal cancer
Giuseppe Nicolò Fanelli, Carlo Alberto Dal Pozzo, Ilaria Depetris, et al.
Oncotarget
|
August 28, 2016
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
Claudia M Hattinger, Paola Biason, Erika Iacoboni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2006
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli, Erika Cecchin, Giuseppe Corona, et al.
Page
of 2